The 5-year age-standardized relative survival was 39.02% for all patients, 58.14% for NK/TCL, 57.60% for ALCL, 31.38% for AITL, and 29.18% for PTCL-NOS. The gene discussed is RHOJ; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.